Equity Capital Markets
We have Ireland’s leading practice in new issue work, advising on initial public offerings and secondary issues of shares and other securities on the Irish, London and New York Stock Exchanges and other international markets, acting both on issuer and underwriter mandates.
We have advised on Ireland’s largest capital raisings and the most innovative investment and capital structures.
Our ECM team also has extensive experience advising listed companies on using their shares as consideration for acquisitions, effecting share buybacks (including by way of accelerated share repurchase), share consolidations/splits, as well as reorganisations and reductions of capital for listed companies.
Relevant Experience
- Advising on the initial public offerings of Aer Lingus, Allegion, Allied Irish Banks, Applegreen, eircom, Fleetmatics, GH Research, Globoforce, Green REIT, Mallinckrodt, Nabriva Therapeutics, Nexvet, nVent, Paddy Power, Presbia, Prothena, Strongbridge Biopharma and TVC Holdings
- Advising Total Produce on its merger with Dole, and the IPO of Dole on the NYSE
- Advising the underwriters on the IPO of GH Research plc (Nasdaq)
- Advising Fusion Fuel on its IPO through a merger with HL Acquisitions Corp., a SPAC (Nasdaq)
- Advising Euroclear on the migration of settlement of Irish equity securities from CREST to Euroclear Bank as a result of Brexit, and advising issuer clients on the shareholder meetings and other arrangements to facilitate this transfer
- Advising Flutter Entertainment plc (London; Dublin) on placings worth almost £2 billion
- Advising Hammerson (London) on its secondary listing on Euronext Dublin
- Advising Greencore plc (London) on its £90 million share placing
- Advising on the US$83 billion merger of Linde and Praxair, and the listing of the merged entity on the NYSE and Frankfurt Stock Exchange
- Advising the sponsors on €12 billion IPO of Allied Irish Banks in London and Dublin
- Advising Strongbridge Biopharma (Nasdaq) on the disposal of certain assets to Novo Nordisk for €145 million;, and a 10% strategic investment in Strongbridge by Novo Nordisk
- Advising Aryzta A.G. on its €800 million underwritten rights issue and the resulting admission of shares on the SIX Swiss Exchange and Euronext Dublin
- Advising Bank of Ireland on the insertion of its new holding company and re-listing its shares in London and Dublin
Insights Blog
ESAP Regulation published in Official Journal; timing confirmed
20/12/2023
Insights blog
ESAP: Platform for public information on companies and financial products to go live in 2027
28/11/2023
Insights blog
New EU Recovery Prospectus will Assist in Raising Capital
08/03/2021
Insights blog
ESMA Guidelines on Disclosure Requirements under the EU Prospectus Regulation
05/03/2021
Insights blog
Related Content
Arthur Cox shortlisted in IFLR Europe Awards 2024
12/02/2024
Awards
40 lawyers recognised in IFLR1000 2023 rankings
20/09/2023
Awards
Arthur Cox advises on 13 of the Finance Dublin Deals of the Year 2023
02/06/2023
News
Arthur Cox advises on 14 of the Finance Dublin Deals of the Year 2022
01/06/2022
Awards
Fusion Fuel IPO through merger with HL Acquisitions Corp.
11/12/2020
Deals
Arthur Cox named European Corporate Team of the Year
02/12/2020
News
Arthur Cox advises Greencore on successful £90 million share placing
24/11/2020
Deals
Arthur Cox advises Aptiv PLC on its Concurrent Ordinary Shares and Mandatory Convertible Preferred Shares Offerings
16/06/2020
Deals
Arthur Cox advises Flutter Entertainment on its successful share placing raising gross proceeds of £812.6 million
29/05/2020
Deals
Five New Partners at Arthur Cox
11/01/2019
Appointments
A voluntary or mandatory EU Green Bond Standard? The debate continues
23/05/2022
Article
Equity Capital Markets in Ireland: Regulatory Overview
09/02/2022
Publication
Company Law: Back to Basics – Directors Conflict of Interest
27/04/2021
Podcast